A detailed history of Captrust Financial Advisors transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 18,000 shares of OCUP stock, worth $20,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,000
Previous 18,000 -0.0%
Holding current value
$20,880
Previous $36,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$3.35 - $4.33 $3 - $4
-1 Reduced 0.01%
18,000 $60,000
Q2 2023

Aug 14, 2023

SELL
$3.63 - $6.38 $5,445 - $9,570
-1,500 Reduced 7.69%
18,001 $78,000
Q1 2023

May 15, 2023

BUY
$3.01 - $3.85 $58,698 - $75,078
19,501 New
19,501 $73,000
Q3 2022

Nov 16, 2022

BUY
$1.82 - $2.79 $32,761 - $50,222
18,001 Added 1200.07%
19,501 $39,000
Q2 2022

Aug 23, 2022

SELL
$1.8 - $3.25 $1 - $3
-1 Reduced 0.07%
1,500 $3,000
Q2 2022

Aug 16, 2022

BUY
$1.8 - $3.25 $1 - $3
1 Added 0.07%
1,501 $3,000
Q1 2022

May 16, 2022

BUY
$2.75 - $4.39 $4,125 - $6,584
1,500 New
1,500 $5,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $23.9M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.